Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 43063-790

7 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43063-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxybutynin 1)

Chemical Structure (Oxybutynin 1)
Chemical structure diagram of oxybutynin chloride, showing molecular components and bonds including cyclohexyl, phenyl, and ethyl groups, as well as hydrochloride (HCl) salt form.*
FDA Label Image

Figure 1 (Oxybutynin 2)

Figure 1 (Oxybutynin 2)
A line graph comparing mean plasma oxybutynin concentration (ng/mL) over 24 hours between oxybutynin chloride extended-release tablets and oxybutynin 5 mg taken three times daily (TID). The x-axis represents time (hours), and the y-axis shows mean plasma concentration with error bars indicating variability.*
FDA Label Image

Figure 2 (Oxybutynin 3)

Figure 2 (Oxybutynin 3)
A line graph depicting the mean plasma concentration of R-Oxybutynin over time in hours, ranging from 0 to 24 hours. The y-axis represents concentration in ng/mL, from 0 to 2.0. Data points with error bars show concentrations peaking around 5 hours and then gradually declining by 24 hours.*
FDA Label Image

Figure 2 (Oxybutynin 4)

Figure 2 (Oxybutynin 4)
A horizontal bar chart showing the mean change (± SD) in episodes per week from baseline for Oxybutynin chloride extended-release tablets compared to placebo. The x-axis ranges from -40 to 40, with zero marked in the center.*
FDA Label Image

Figure 3 (Oxybutynin 5)

Figure 3 (Oxybutynin 5)
A horizontal bar chart displaying the mean change in episodes per week from baseline for oxybutynin chloride extended-release tablets. The chart includes error bars indicating standard deviation, with values ranging approximately from -40 to +40 episodes per week on the horizontal axis.*
FDA Label Image

Figure 4 (Oxybutynin 6)

Figure 4 (Oxybutynin 6)
Line graph titled 'Oxybutynin chloride extended release tablets' showing the mean change and standard deviation in episodes per week from baseline. The x-axis ranges from -40 to 40, depicting the reduction or increase in episodes, with data points presented for both oxybutynin and placebo groups over time.*
FDA Label Image

43063790 Label (43063790)

43063790 Label (43063790)
Medication label for Oxybutynin Chloride Extended Release 10 mg tablets, 90 count. The label includes the NDC 43063-790-90 and is manufactured by PD-Rx Pharmaceuticals, Incorporated in Oklahoma City, OK. It features warnings about drowsiness and alcohol consumption, dosage instructions, reorder number, lot number G19F10, and expiration date 07/2021. The label also displays a barcode and a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.